PUBLIC COMPANY
save$DSGNDesign Therapeutics, Inc.
$DSGN12.50-0.56%Carlsbad, CA, USupdated 3h ago
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(1)
pipeline depth1 products
1Phase 2
Upcoming
no upcoming catalysts on record
Recent(90d)
earnings (1)
Active trials
- phase2DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy
- phase2A Multiple Ascending Dose Study of DT-216P2 in Patients With Friedreich's Ataxia
- phase1A Single Ascending Dose Study of DT-216P2 in Normal Healthy Participants
- phase1Study to Evaluate Multiple Ascending Dose and Multi-Dose of DT-216 in Adult Patients With Friedreich Ataxia
🐶 Hiring Signal
News
- STAT+: Up and down the ladder: The latest comings and goingsFrom new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.stat · 3mo ago
Data sources
last refreshed 56m ago
Found something off?
comments(0)
5-min edit window · permanent after that